The historical antimalarial compound endochin served as a structural lead for optimization. Endochin-like quinolones (ELQ) were prepared by a novel chemical route and assessed for in vitro activity against multidrug resistant strains of Plasmodium falciparum and against malaria infections in mice. Here we describe the pathway to discovery of a potent class of orally active antimalarial 4(1H)-quinolone-3-diarylethers. The initial prototype, ELQ-233, exhibited low nanomolar IC 50 values against all tested strains including clinical isolates harboring resistance to atovaquone. ELQ-271 represented the next critical step in the iterative optimization process, as it was stable to metabolism and highly effective in vivo. Continued analoging revealed that the substitution pattern on the benzenoid ring of the quinolone core significantly influenced reactivity with the host enzyme. This finding led to the rational design of highly selective ELQs with outstanding oral efficacy against murine malaria that is superior to established antimalarials chloroquine and atovaquone.
■ INTRODUCTION
Malaria is a deadly disease that has plagued human civilization down through recorded history and has been responsible for the deaths of millions, particularly infants, young children, and expectant mothers. 1 While progress has been made over the past decade to lessen the impact of the disease on global health, widespread multidrug resistance threatens to reverse recent gains brought about by the use of insecticide-treated bed nets and artemisinin-combination therapies. New drugs that are active against multiple stages of the Plasmodium parasite's life cycle, including transmissible forms in the host and mosquito vector, will be important for pressing forward with a worldwide effort to contain and eliminate malaria from the many countries where it remains endemic. 2 Interest in the antimalarial properties of 3-alkyl-4(1H)quinolones dates to the 1940s and the pioneering research led by Hans Andersag at Bayer IG Farbenindustrie in Elberfeld, Germany. 3 Their work on this particular class of molecules focused principally on endochin (see Figure 1 ) because it was highly active against blood and tissue stages of avian malaria (Plasmodium cathemerium in canaries), a preclinical model system in use at the time. 4 However, their attempts to demonstrate efficacy with endochin in humans failed. Recently we showed that endochin is extensively metabolized (including O-demethylation as well as hydroxylation of the ring nitrogen and heptyl side chain) to poorly active metabolites by human hepatic microsomal enzymes, thus providing one possible explanation for the patient treatment failures over six decades ago. 5 With intent to develop an endochin-like quinolone (ELQ) that targets multiple stages of the malaria life cycle, we set out to design derivatives with enhanced metabolic stability and potent activity against drug resistant malaria. Our early work 5 showed that endochin analogues with a halogen at the 6-position, such as ELQ-130 (1) (Figure 1 ), were equipotent against Plasmodium falciparum strains resistant to chloroquine, quinine, mefloquine, and the folate antagonists, pyrimethamine and sulfadoxine, as well as the antirespiratory compound atovaquone ( Figure 2 ).
Our studies revealed that ELQs effectively shut down the parasite respiratory processes within minutes following drug addition. 6 A carbonate prodrug of a potent endochin analogue, 5,7-difluoro-3heptyl-2-methylquinolin-4(1H)-one, was curative against patent malaria infections in mice, albeit at relatively high doses of 50−100 mg/kg/day. 5 At this point, we joined a research consortium supported by the Medicines for Malaria Venture (Geneva, Switzerland) for chemical optimization of endochin. We proposed to replace the metabolically labile heptyl side chain at position 3 of endochin with a substituted diarylether, taking a cue for this from Yeates and co-workers, 7 who described a series of diphenylether containing pyridones that, like atovaquone, mimic the structure of coenzyme Q and target the Plasmodium cytochrome bc 1 complex. 7, 8 A late lead from this series, GW844520, appears in Figure 2 . Another clue to this modification came from earlier work by Fieser and colleagues, who described an antimalarial hydroxynaphthoquinone containing a 3-alkyl-diphenylether side chain (designated M-2309, Figure 2 ) with enhanced metabolic stability. 9 We report here the discovery of 4(1H)-quinolone-3diarylethers and the in vitro and in vivo structure−activity profiles that significantly impacted the optimization path toward the design and selection of a preclinical candidate with the potential for prevention and treatment of malaria and for interfering with disease transmission.
■ CHEMISTRY
Iodination of commercially available 4(1H)-quinolone 9a with iodine in saturated aqueous potassium iodide solution and n-butylamine provided the 3-iodo-4(1H)-quinolone 10a (Scheme 1). Direct Suzuki−Miyaura reaction of 10a with 4-phenoxyphenyl boronic acid resulted in an inseparable mixture of products. 4(1H)-Quinolones suffer from low solubility in almost all solvents and are thus difficult to isolate chromatographically. Mphahlele and Mtshemla showed that 3-aryl-4(1H)-quinolones could be prepared via Suzuki−Miyaura reaction of 3-iodo-4-methoxyquinolones. 10 Conversion of 10a to the corresponding 4-chloro-3-iodoquinoline in neat phosphorus oxychloride followed by nucleophilic displacement of the chloro substituent with sodium methoxide provided 3iodo-4-methoxyquinolone 11a. Suzuki−Miyaura reaction of 11a with phenoxyphenylboronic acid in the presence of palladium tetrakis triphenyphosphine (0) and aqueous potassium carbonate provided 4-methoxyquinolone-3-diarylether 12a. Removal of the methyl ether-protecting group with 3 equiv of BBr 3 provided the desired 4(1H)-quinolone-3-diarylether ELQ-233 (3) ( Figure 1 ) in excellent overall yield.
Because the lead compound, endochin, has a methoxy group at the 7-position, it was important to demonstrate that the quinolone 4-methoxy ether could be selectively cleaved in the presence of an aryl methoxy moiety. Thus, the synthesis of 4(1H)-quinolone-3-diarylether ELQ-262 (13) was undertaken. Condensation of commercially available 4-fluoro-3-methoxyaniline 8b and ethyl acetoacetate followed by thermal cyclization provided 2-methyl-4(1H)-quinolone 9b via Conrad−Limpach synthesis. 11 Iodination using the method described above followed by selective oxygen alkylation using methyl iodide and potassium carbonate provided the 3-iodo-4-methoxyquinolone 11b. 4-Methoxyquinolone-3-diarylether 12b was obtained from 11b using the Suzuki reaction described above. However, deprotection of 12b with 3 equiv of BBr 3 resulted in the cleavage of both methyl ethers. Various selective deprotection methods were evaluated by HPLC including less BBr 3 (1.5 equiv), refluxing 48% aqueous HBr, and refluxing 1:1 48% aqueous HBr and acetic acid. However, it was not possible to selectively deprotect the 4-methoxy position in the presence of the 7methoxy moiety. Considering that an ethyl group would form a more stable carbocation intermediate under acidic cleavage conditions compared to the corresponding methyl ether, we prepared 4-ethoxyquinolone-3-diarylether 12c. Deprotection of 12c in 1:2 48% aqueous HBr and acetic acid at 90°C gave complete and selective conversion to 4(1H)-quinolone-3diarylether 13.
The boronic ester of the trifluoromethoxy diarylether side chain 16a was then prepared (Scheme 2). Copper-mediated coupling of commercially available 4-bromophenol and 4trifluoromethoxyphenyl boronic acid 14a with Hunig's base and pyridine afforded the bromo diarylether 15a. 12 Palladiummediated coupling of 15a and bis(pinacolato) diboron with potassium acetate gave the desired boronic ester 16a. A series of benzenoid ring substitituted 4(1H)-quinolone-3-diarylethers (Table 1) was prepared from the appropriate 3-iodo-4-ethoxyquinolones 11c−h and boronic ester 16a using the above method. A series of 4(1H)-quinolone-3-diarylethers varying in the side chain portion of the molecule (Table 3) was prepared from 3-iodo-4-ethoxy-quinolone 11g and the appropriate boronic esters 16b−g also using the above method.
Preparation of heterocyclic diarylethers using the copper (II) acetate coupling described above proved problematic. However, a series of heterocyclic diarylether compounds (22a−c and 28) was prepared by coupling of commercially available aryl iodides 21a−c with 4-trifluoromethoxy phenol (Scheme 3) or by coupling of 4-bromophenol with 1-iodo-4-trifluoromethylpyridine (Scheme 4) in the presence of copper (I) iodide, picolinic acid, and tribasic potassium phosphate. 13 A series of 4(1H)quinolone-3-diarylethers with heterocyclic side chains ( Table 4 ) was prepared using the above method.
■ RESULTS AND DISCUSSION
Here we describe some of the key compounds and assays that helped to guide us through the discovery phase and to accelerate the optimization process leading to highly active molecules of the 4(1H)-quinolone-3-diarylether class of antimalarials. At the outset of research activities with the Medicines for Malaria Venture, the primary challenges to endochin optimization were Table 1 . Optimization of Benzenoid Ring Substituents a a clogP values were calculated using ChemDraw Ultra software (version 12). EC 50 values are the average of at least three determinations, each carried out in triplicate. Cytotoxicity assays (IC 50 values) were carried out with human hepatoma derived HepG2 cells and performed in triplicate across an initial concentration range of 2.5 nM to 10 μM. Full details of each of these biological and biochemical assays can be found in the Experimental Section. ND = not determined. clear: (1) enhance metabolic stability, (2) enhance aqueous solubility, (3) eliminate cross-resistance in clinical strains of P. falciparum, and (4) diminish the propensity for resistance, i.e., relative to atovaquone for which resistance arises quickly.
Early in the analoging work we obtained X-ray diffraction analysis of the crystal structure for the endochin derivative 5,7-difluoro-3-heptyl-2-methylquinolin-4(1H)-one. 5 The crystal structure revealed extensive π−π stacking in the Z plane and an extensive network of intermolecular H-bonds in the X−Y plane (see Supporting Information Figure S1 ). A decision was made to place an aryl group at position 3 because the adjacent 2-position CH 3 would force an out-of-plane movement of the bulky aromatic ring, thereby potentially disrupting π−π interactions and reducing the crystal lattice energy. We chose the lipophilic diphenylether moiety because it was a key structural element for the highly active antimalarial GSK pyridones 7, 14 and earlier 2-hydroxy-naphthoquinones from Fieser's research program. 9, 15 All of the compounds were evaluated for parasite growth inhibitory activity in vitro by a microplate-based assay in which SyBr Green 1 fluorescent dye was utilized to quantitate parasite double stranded DNA following a 72 h incubation period. 16 In vivo efficacy was determined in a murine Plasmodium yoelii model in which animals were randomly placed in groups of four and administered test drugs by oral gavage on four sequential days following the day of inoculation. The in vivo data are expressed as ED 50 values and reflect the dose (estimated from dose− response curves) for suppression of parasitemia by 50% relative to vehicle-only controls as assessed on day 5 of each study. Drug treated animals that were parasite free on day 30 of the experiment are defined as "cures", and the amount of drug that was needed to achieve a cure is referred to as the "nonrecrudescence dose" (NRD).
Compounds 3 and 13 were prepared as described above from commercially available phenoxyphenylboronic acid. Unsubstituted in the benzenoid ring of the quinolone core, compound 3, the first compound in this subseries, showed equipotency (EC 50 values 10 nM) against all three tested strains including multidrug resistant strains and an atovaquone-resistant clinical isolate Tm90-C2B (Table 1 ). Compound 13, with a fluorine atom at position 6 and a methoxy group at position 7, also exhibited impressive low nanomolar EC 50 values against all three strains. Both of these compounds were metabolically unstable in the presence of rat and human liver microsomes ( Table 2 ) with in vitro degradation half-lives of 10.6−92.7 min and microsomepredicted hepatic extraction ratios (E H ) in the intermediate to high range of 0.5−0.8. In contrast, there was no detectable degradation in the microsomal matrix with ELQ-271 (4) ( Figure 1 ), and the intrinsic antiplasmodial activity was enhanced about 2-fold over its progenitors. Clearly, the introduction of an OCF 3 group at the para position of the outermost ring of the diarylether side chain stabilized the drug against liver derived microsomal enzymes.
The effect of substituents on the benzenoid ring of the quinolone core was further explored to optimize the scaffold for potency and lack of cross-resistance, focusing especially on the Table 2 . Optimization of Benzenoid Ring Substituents: Metabolic Stability and in Vivo Efficacy a a Detailed procedures for assay of microsomal stability and for in vivo assessment of antimalarial activity against P. yoelii infected mice can be found in the Experimental Section. ND = not determined. atovaquone resistant isolate. On the basis of earlier work by Andersag relating to endochin (which exhibits modest cross resistance vs Tm90-C2B), our earlier discovery of 6-position halogenated variants 1 and 6-fluoro-3-heptyl-2-methylquinolin-4(1H)-one (i.e., lack of atovaquone cross resistance), 5 as well as the 6-Cl/7-OCH 3 combination provided by WR-109,878 (2) as published previously by Cross et al. 17 (and also lacking atovaquone cross resistance), we completed the synthesis of ELQ-296 (5), ELQ-298 (6), ELQ-300 (7), ELQ-314 (18a), and ELQ-316 (18b) (Scheme 2). In vitro microsomal assays showed Table 3 . Optimization of Diarylether Side Chain: Substituents a a clogP values were calculated using ChemDraw Ultra software (version 12). EC 50 values are the average of at least three determinations, each carried out in triplicate. Cytotoxicity assays (IC 50 values) were carried out with human hepatoma derived HepG2 cells and performed in triplicate across an initial concentration range of 2.5 nM to 10 μM. Full details of each of these biological and biochemical assays can be found in the Experimental Section. ND = not determined. 
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Article dx.doi.org/10.1021/jm500147k | J. Med. Chem. 2014, 57, 3818−3834 that 6 was metabolized at a moderate to intermediate rate in both rat and human hepatic microsomal mixtures, while the other compounds in this set were highly stable to metabolism. All of these molecules exhibited low nanomolar EC 50 values against P. falciparum strains D6, Dd2, and Tm90-C2B. It is noteworthy that compound 7 was also highly active against P. falciparum strain Tm93-C1088 with an EC 50 value of 1.0 nM (see Supporting Information Table S2 ). Like Tm90-C2B, this parasite 18 was isolated from a Thai patient who experienced a recrudescence of parasitemia after treatment with atovaquone. The inhibitory effect of this subseries of molecules was highly specific, as evidenced by the lack of cytotoxicity exhibited by any member of the set against proliferating HepG2 cells (a human hepatoma cell line) at concentrations as high as 10 μM.
The in vivo antimalarial efficacy of this initial series of ELQ derivatives is summarized in Table 2 and compared to endochin, the original lead, as well as chloroquine, a 4-aminoquinoline antimalarial drug. Consistent with earlier reports and our observation that it is metabolically unstable, endochin was inactive in vivo while the estimated ED 50 value for chloroquine was 2.2 mg/kg/day (CQ was not curative in this model even at doses as high as 64 mg/kg/day). With the minimum structural elements needed for potency and metabolic stability, 4 showed a dramatic enhancement of in vivo efficacy over endochin with an ED 50 value of 0.1 mg/kg/day and parasite-free cures, established on day 30, at 3 mg/kg/day. The 6-chloro analogue (5) was much less effective than 4, which may relate to low aqueous solubility and poor oral bioavailability. Compound 7 (delivery vehicle: PEG400), with the 6-Cl/7-OCH 3 substitution pattern, provided excellent in vivo values against P. yoelii in mice with ED 50 and ED 90 values of 0.02 and 0.06 mg/kg/day, respectively, and a nonrecrudescence cure dose of 0.3 mg/kg/day. It is noteworthy that 7 was shown previously to be 30-fold more effective than atovaquone against murine malaria in side-by-side tests. 19 The 6-F and 6-F/7-OCH 3 analogues (i.e., 18a and 18b) within this series, with reduced cLogP values relative to 7, were also highly Table 4 . Optimization of Diarylether Side Chain: N-Heterocycles a a clogP values were calculated using ChemDraw Ultra software (version 12). EC 50 values are the average of at least three determinations, each carried out in triplicate. Cytotoxicity assays (IC 50 values) were carried out with human hepatoma derived HepG2 cells and performed in triplicate across an initial concentration range of 2.5 nM to 10 μM. Full details of each of these biological and biochemical assays can be found in the Experimental Section. ND = not determined. active in vitro and stable to metabolism. However, they were somewhat less efficacious against malaria in mice, which may relate to differences in pharmacokinetics.
It is important to note that a prodrug of the GSK pyridone progressed until toxicology results revealed unexpected acute toxicity in rats that was putatively linked to inhibition of mammalian cytochrome bc 1 complex. 14 Because of the close structural similarity between the pyridone and 4(1H)-quinolonediarylethers and out of concern for potential host toxicity, each of the 4(1H)-quinolone-3-diarylethers in the original set (4−7 and 18a−b) was screened for inhibition of human cytochrome bc 1 complex (derived from HEK-293 cells) activity ( Figure 3 ). An interesting SAR trend emerged from the in vitro inhibition profile. For 4, in which each position of the core benzenoid ring is occupied by an H atom, the IC 50 level against host cytochrome bc 1 was 1.85 μM. ELQs with a 6-position halogen atom (e.g., compound 5 and 18a) or a −OCH 3 group in position 7 (e.g., compound 6), or both (e.g., compounds 7 and 18b), were not inhibitory toward the human enzyme at concentrations as high as 10 μM. Evaluation of 7 for inhibition of P. falciparum cytochrome bc 1 complex provided an EC 50 value of 0.56 nM, thereby highlighting the remarkable parasite selectivity (≥20000-fold) of this analogue as well as its superiority over 4 (IC 50 = 8.9 nM) and atovaquone (IC 50 = 2 nM) as inhibitory molecules in this assay. 19 Overall, we observed that the degree of host vs parasite selectivity increased as the size of the core increased from the pyridone to the quinolone ring system. We assume that this is due to steric hindrance in binding of the larger quinolone core to the more restrictive Q i site of the human cytochrome bc 1 . The evidence further shows that addition of bulky substituents to the 6-or 7position widens the selective advantage and minimizes the potential developmental risk associated with the inhibition of host cytochrome bc 1 complex.
Other structural variations were explored including the meta-OCF 3 congener of 7. This compound, ELQ-307 (20a), exhibited spectacular activity in vitro against P. falciparum; however, it was metabolically unstable in the presence of hepatic microsomes and ineffective in vivo. In an attempt to capture the high intrinsic activity of 20a in a metabolically stable form, we prepared ELQ-352 (20e), which added a fluoro substituent ortho to the trifluoromethoxy group in 20a. While 20e had an excellent antiplasmodial profile with subnanomolar EC 50 values against all three reference strains, it was both less potent than 20a in vitro and far less effective than 7 in vivo. This result indicated that there is sensitivity to the SAR in this region, and the fluoro substituent diminished exposure and efficacy as a consequence. To demonstrate this, ELQ-353 (20f) was prepared, which added a meta-fluoro substituent to 7. With decreased in vitro potency and in vivo efficacy relative to 7, compound 20f confirmed the findings that even a small modification to 7 results in a decrease in activity.
Finally, the 4(1H)-quinolone-3-diarylether series described here includes molecules with a high selectivity index against the parasite mitochondrial electron transport chain. Potent against all life cycle stages of P. falciparum including infections in the liver and bloodstream and with particular sensitivity exhibited by developing forms within the mosquito vector, 7 has been selected as a preclinical candidate. 20 In preclinical animal studies, 7 demonstrated nonlinear pharmacokinetics, i.e., at low doses required for a therapeutic effect oral bioavailability was good to excellent from the PEG400 solution formulation, however, it fell off rapidly at higher doses, presumably due to solubility limited absorption. 19 A focused medicinal chemistry plan was developed to address the poor aqueous solubility and oral bioavailability issues that limit exposures of 7 at higher doses that are needed to establish a therapeutic safety window. Side chain analogues with reduced cLogP values in which the terminal OCF 3 moiety was replaced by CF 3 (ELQ-309, 20b), Cl (ELQ-323, 20c), and F (ELQ-333, 20d) exhibited impressive antiplasmodial activity with EC 50 values in the low to subnanomolar range. In vitro tests revealed that they were metabolically stable in the presence of human and rat microsomes. The introduction of nitrogen atoms in the form of pyridyl or pyrimidyl rings at either the inner or outermost rings of the diarylether yielded ELQs with excellent, e.g., ELQs 310 (25a) and 313 (25b), to poor ELQ-329 (25c), in vitro activity against P. falciparum. Unfortunately, none of the compounds that were selected for further study from this series (25a and 20c) provided a significant enhancement over the blood levels achieved with 7 at oral doses of 1 and 10 mg/kg, and they were at least 3−10 times less effective than 7 against murine malaria.
■ SUMMARY AND CONCLUDING REMARKS
Our interest in endochin derived from earlier work on the larger acridone scaffold. 21 The hydrolysis of quinacrine produced an acridone (3-chloro-7-methoxyacridone) with impressive antiplasmodial and antirespiratory properties, and this same molecule also served as the catalyst for Hans Andersag's optimization program that spotlighted endochin for its pronounced effectiveness against multiple stages of malaria infection. 3 Our efforts to chemically alter the structure of endochin to enhance its clinical utility have shown that additions to the benzenoid ring of the quinolone core have the greatest influence on intrinsic antiplasmodial activity, cross-resistance, and selective inhibition of host and parasite cytochrome bc 1 complexes. The 6-Cl/7-OCH 3 substitution pattern yielded analogues that were not cross resistant to atovaquone, a highly desirable attribute given that atovaquone is a key component of a clinical formulation with proguanil that is used in treatment of malaria. Replacement of endochin's extended alkyl group with a diphenylether at position 3 resulted in >1000-fold greater efficacy in vivo compared to the original lead molecule. Presumably, the overall boost in antimalarial efficacy in going from endochin to 7 is due to the presence of the 3-position diphenylether side chain that imparts enhanced metabolic stability while maintaining acceptable, albeit low, aqueous solubility. 19 In summary, we discovered a novel route to synthesis of 3diarylether substituted 4(1H)-quinolones. Unable to find reaction conditions that would allow for the selective deprotection of 4-O-methylether quinoline intermediates in the presence of an essential core methoxy group, we devised a successful route through the corresponding 4-O-ethylethers. The parallel convergent approach that is described is straightforward, utilizes inexpensive and readily available reagents, yields the desired quinolone in high purity (>99%), and is amenable to large-scale production. All of these factors are important given that antimalarial drugs need to be inexpensive so that they can be made available to populations in need in the developing world where the disease is endemic and resources are limited.
One of the greatest challenges to the clinical development of 7 for human use against malaria is the identification of a clinical formulation that improves exposures at higher doses needed to establish safety and tolerability in preclinical species and humans. Higher doses are also needed to establish whether and if it would be feasible to use 7 to achieve one-dose cures of falciparum malaria. Conventional formulation technologies such as particle size reduction, 22 use of solubilizing excipients or complexation agents, 23 as well as the development of amorphous spray-dried dispersions 24 and prodrugs 25 are all part of an ambitious program of research that is currently underway to resolve this issue so that the clinical potential for this new drug can be fully explored.
■ EXPERIMENTAL SECTION
General Chemistry. Anhydrous solvents and reagents were purchased from various fine chemical suppliers and were used without further purification. Inert atmosphere operations were conducted under argon in flame-dried glassware. 1 H NMR spectra were taken on a Bruker 400 MHz instrument. Data reported were calibrated to internal TMS (0.0 ppm) for all solvents and are reported as follows: chemical shift, multiplicity (bs, broad singlet; s, singlet; d, doublet; t, triplet; q, quartet; and m, multiplet), coupling constant, and integration. High-resolution mass spectrometry (HRMS) using electrospray ionization was performed by the Portland State University BioAnalytical Mass Spectrometry Facility. Final compounds were judged to be >95% pure by HPLC analysis using an HP1100 HPLC at 254 nm with Phenomenex Luna C8(2) reverse phase column (5 mm, 50 mm × 2 mm i.d) at 40°C and eluted with methanol/water with 0.5% TFA and acetonitrile/water with 0.5% TFA at 0.4 mL/min. Further information is provided in the Supporting Information accompanying this report in which we have employed this separation system to characterize the relative hydrophobicity for each of the synthesized 4(1H)-quinolone-3-diarylethers (i.e., retention time) and correlated these results to cLogP values calculated with ChemDraw Ultra software (Cambridgesoft, version 12).
General Procedure A. A solution of aniline (63.5 mmol), ethyl acetoacetate (63.5 mmol), and catalytic para-toluene sulfonic acid (1.59 mmol) in 65 mL of benzene was stirred 6 h at reflux with a Dean− Stark trap. The reaction mixture was then concentrated in vacuo and the resulting Schiff base added to 65 mL of boiling (250°C) DOWTHERM A and stirred 20 min at 250°C. The reaction mixture was cooled to room temperature. After trituration with ethyl acetate, the product 4(1H)-quinolone was collected by filtration.
General Procedure B. To a stirred solution of 4(1H)-quinolone (62.2 mmol) and n-butylamine (622 mmol) in dimethylformamide (125 mL) cooled by a room temperature water bath was added iodine (62.2 mmol) in a saturated solution of aqueous potassium iodide (62 mL). The reaction mixture was stirred 12 h at room temperature. Residual iodine was quenched with excess 0.1 M aqueous sodium thiosulfate, and the resulting solution was concentrated in vacuo. The residue was resuspended in water and filtered to give the product 3-iodo-4(1H)-quinolone.
General Procedure C. To a stirred solution of 3-iodo-4(1H)quinolone (5.72 mmol) in dimethylformamide (57 mL) was added potassium carbonate (11.4 mmol) at room temperature. The resulting suspension was stirred 0.5 h at 50°C. Ethyl iodide (8.58 mmol) was added dropwise at room temperature, and the reaction mixture was General Procedure E. Using a method adapted from Maiti and Buchwald, 13 to a flask containing aryl iodide (5.00 mmol), phenol (6.00 mmol), copper (I) iodide (0.500 mmol), picolinic acid (1.00 mmol), and potassium phosphate (10.0 mmol) was added dry DMSO (10 mL). The reaction mixture was heated to 80°C, stirred for 18 h, and allowed to cool. The reaction was then diluted with ethyl acetate (50 mL) and water (5 mL) and separated. The aqueous phase was extracted with ethyl acetate (2 × 50 mL). The combined organic phases were treated with brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by flash chromatography (ethyl acetate/hexanes).
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General Procedure F. To a solution of bromo diaryl ether (33.0 mmol) in DMF (130 mL) over heat-activated 3 Å molecular sieves (13 g) was added 1,1′-bis(diphenylphosphino)ferrocene dichloropalladium (II) (1.65 mmol), bis(pinacolato) diboron (36.3 mmol), and potassium acetate (99.0 mmol). The reaction mixture was heated to 80°C, stirred for 18 h, cooled, and filtered. The filtrate was concentrated in vacuo, resuspended in ethyl acetate and water, and separated. The organic layer was extracted with brine and dried over magnesium sulfate. Purification by silica gel chromatography (ethyl acetate/hexanes) provided the product boronic ester.
General Procedure G. To a solution of 3-iodo-4(1H)-quinolone O-ethyl ether (3.35 mmol), boronic acid/ester (5.02 mmol), and palladium (0) tetrakis triphenylphosphine (0.168 mmol) in degassed dimethylformamide (17 mL) was added 6.7 mL of a 2 N aqueous potassium carbonate solution. The reaction mixture was stirred 18 h at 85°C, filtered through celite, and concentrated in vacuo. The resulting residue was resuspended in ethyl acetate and water and separated. The organic layer was extracted with brine, dried over magnesium sulfate, and concentrated in vacuo. Purification by silica gel chromatography (ethyl acetate/dichloromethane) provided the product 4(1H)-quinolone O-ethyl ether.
General Procedure H. To a solution of 4(1H)-quinolone O-ethyl ether (2.30 mmol) in acetic acid (10 mL) was added a 50% aqueous hydrobromic acid solution (5 mL). The reaction mixture was stirred 24 h at 90°C, cooled, and neutralized with a saturated potassium hydroxide solution. The product 4(1H)-quinolone-3-diaryl ether was triturated in ethyl acetate and recrystallized from DMF/methanol.
2-Methyl-3-(4-phenoxyphenyl)quinolin-4(1H)-one (3). To a solution of 4-methoxy-2-methyl-3-(4-phenoxyphenyl)quinoline 12a (1.60 mmol) in anhydrous dichloromethane (12 mL) was added boron tribromide (0.23 mL) at room temperature. The reaction mixture was stirred 18 h at room temperature, quenched with 10 mL of water, and filtered. The filter cake was triturated in ethyl acetate and recrystallized from methanol to give the title compound as a flaky offwhite solid (314 mg, 60% yield). 1 6-Chloro-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl)quinolin-4(1H)-one (5) . The title compound was prepared from 6-chloro-4-ethoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl)quinoline 17b according to general procedure H. Yield: 73%. 1 6-Chloro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl) quinolin-4(1H)-one (7) . The title compound was prepared from 6-chloro-4-ethoxy-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl) quinoline 17d according to general procedure H. Yield: 84%. 1 3-Iodo-7-methoxy-2-methylquinolin-4(1H)-one (10d). The title compound was prepared from 7-methoxy-2-methylquinolin-4(1H)-one 9d according to general procedure B. Yield: 88%. 1 6-Chloro-3-iodo-7-methoxy-2-methylquinolin-4(1H)-one (10e). The title compound was prepared from 6-chloro-7-methoxy-2methylquinolin-4(1H)-one 9e according to general procedure B. Yield: 89%. 1 3-Iodo-4-methoxy-2-methylquinoline (11a). A solution of 4hydroxy-3-iodo-2-methylquinolone 10a in phosphorus oxychloride (80 mL) was refluxed 3 h. The reaction mixture was cooled to 0°C, quenched with a cold, saturated sodium hydroxide solution, and extracted with ethyl acetate. The organic layer was extracted with brine, dried over magnesium sulfate, filtered, and concentrated in vacuo to give 4-chloro-3-iodo-2-methylquinoline (6.68 g, 88% yield) as an off-white solid. 4-Chloro-3-iodo-2-methylquinoline (1.55 g, 5.11 mmol) was added to a solution of sodium metal (1.00 g, 43.5 mmol) in dry methanol (40 mL). 10 The reaction mixture stirred 18 h at reflux and concentrated in vacuo. The resulting residue was resuspended in ethyl acetate and water. The organic layer was extracted with water and brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting off-white solid was recrystallized from hexanes and ethyl acetate to give white crystals (0.866 g, 56% yield). 1 6-Fluoro-3-iodo-4,7-dimethoxy-2-methylquinoline (11b). To a stirred solution of 10b (5.72 mmol) in dimethylformamide (57 mL) was added potassium carbonate (11.4 mmol) at room temperature. The resulting suspension was stirred 0.5 h at 50°C. Methyl iodide (8.58 mmol) was added dropwise at room temperature, and the reaction mixture was stirred 8 h at 50°C. The solvent was removed in vacuo, and the resulting residue was resuspended in ethyl acetate and water and filtered. The organic layer was extracted with brine, dried over magnesium sulfate, and concentrated in vacuo to give the title compound (30% yield) as an offwhite solid. 1 6-Chloro-4-ethoxy-3-iodo-7-methoxy-2-methylquinoline (11g). The title compound was prepared from 6-chloro-3-iodo-7-methoxy-2-methylquinolin-4(1H)-one 10e according to general procedure C. Yield: 99%. 1 4-Ethoxy-6-fluoro-3-iodo-2-methylquinoline (11h). The title compound was prepared from 6-fluoro-3-iodo-2-methylquinolin-4(1H)-one 10f according to general procedure C. Yield: 69%. 1 6-Fluoro-7-methoxy-2-methyl-3-(4-phenoxyphenyl)quinolin-4(1H)-one (13) . The title compound was prepared from 4ethoxy-6-fluoro-7-methoxy-2-methyl-3-(4-phenoxyphenyl)quinoline 12c according to general procedure H. Yield: 89%. 1 1-(4-Bromophenoxy)-3-(trifluoromethoxy)benzene (15b). The title compound was prepared from commercially available 3-(trifluoromethoxy)phenylboronic acid 14b according to general procedure D. Yield: 69%. 1 
